Bone News and Research

RSS

DCR to present data on DaVita Cathaway program at ASN Annual Meeting

DaVita Clinical Research, a provider of clinical research and diagnostic laboratory services, announced today that 56 posters and five oral presentations will be presented by the Company's unsurpassed renal experts at the 43rd American Society of Nephrology (ASN) Annual Meeting and Scientific Exposition from November 16 - 21, 2010, at the Colorado Convention Center located in Denver, Colorado.

19 Nov 2010

Doctors recommend drug holidays from bisphosphonates to enhance bone health

Taking time off from certain osteoporosis drugs may be beneficial to bone health, according to a study conducted at Loyola University Health System. Researchers found that bone density remained stable for three years in patients who took a drug holiday from bisphosphonates, a popular class of osteoporosis drugs that can cause fractures in the thigh bones and tissue decay in the jaw bone.

19 Nov 2010

Medicare committee recommends expensive drug for some prostate-cancer patients

A new treatment for prostate cancer called Provenge won a vote of confidence from a Medicare coverage advisory committee Wednesday, suggesting the federal program is likely to pay for the $93,000-per-patient medicine.

19 Nov 2010

Transplantation of gene-modified hematopoietic stem cells eliminates cancer: Research

A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation.

19 Nov 2010

Aastrom announces interim analysis of Phase 2b RESTORE-CLI clinical trial for treatment failure

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that an interim analysis of all 86 patients enrolled in the company's Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

19 Nov 2010

Scientists discover bone matrix plays a vital role in tissue hardening

Scientists are reporting the first direct evidence that a subtle change in the physical properties of a tissue can affect its function. The finding has immediate implications for understanding several rare hearing disorders, they said, and ultimately could offer insight into such conditions as osteoporosis, arthritis, cardiovascular disease and cancer.

19 Nov 2010

Spleen cells may do more harm than good at site of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

New technique to identify cancer biomarkers

The University of Liège has presented TARGETOME, the most recent of its spin-offs, which is also the first to spring from its applied geno-proteomics centre, GIGA.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

States consider options for funding Medicaid

The Billings Gazette: Montana lawmakers questioned the state's top health official "about plans to hire a private company to manage part of Medicaid, asking why the administration hasn't had a more public discussion on the proposal." The Legislative Finance Committee also listened to "health care providers and former officials who experienced the state's 1995 foray into private management of Medicaid for the mentally ill — and how it became a disaster for its low-income patients and their providers."

18 Nov 2010

Titan Spine granted FDA clearance for Endoskeleton TO system

Titan Spine, a developer of novel interbody fusion implants, announced today that it has received FDA clearance to commercially release its Endoskeleton® TO system, which consists of a line of interbody devices placed through a Posterior Lumbar Interbody Fusion (PLIF) approach. The company plans to commercially release the product beginning in December, 2010.

18 Nov 2010

AACN endorses intraosseous vascular access

Recognizing that IV use is not always optimal to provide patients with fluids and medications, the American Association of Critical-Care Nurses (AACN) recently endorsed a consensus paper that recommends intraosseous (IO) vascular access in a variety of healthcare settings.

17 Nov 2010

Health professionals invited for 1st Asia-Pacific Osteoporosis Meeting

Healthcare providers in the Asia-Pacific region are coping with a rising tide of osteoporotic fractures. The IOF Regionals - 1st Asia- Pacific Osteoporosis Meeting, to take place in Singapore from December 10-13, 2010, is an ideal opportunity for health professionals in the region to acquire the latest practical information on osteoporosis and related fractures.

17 Nov 2010

Cardio3 BioSciences announces positive results from C-Cure Phase II clinical trial for heart failure

The Belgian biotechnology company, Cardio3 BioSciences a leader in discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases today announces positive six-month results, including significant functional and clinical benefit, from the Phase II clinical trial of its development programme C-Cure(R), designed as a novel stem cell therapy for heart failure based on breakthrough technology.

17 Nov 2010

Medtronic acquires Osteotech

Moving to expand its Biologics product offerings, Medtronic, Inc., announced today it has completed the acquisition of Osteotech, following payment of $6.50 per share in cash for each share of Osteotech stock, with a total transaction value of approximately $123 million.

16 Nov 2010

Misonix to introduce OsteoSculpt for facial bone surgery at EACMFS Congress

Misonix, Inc., a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced its attendance and exhibition at the 20th Congress of the European Association for Cranial-Maxillofacial Surgery (EACMFS), which was held recently in Bruges, Belgium.

16 Nov 2010

Merrion prepares Phase III study for Orazol in breast cancer treatment

After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.

16 Nov 2010

Research suggests targeting spleen may promote healing of spinal cord injury

The spleen, an organ that helps the body fight infections, might also be a source of the cells that end up doing more harm than good at the site of a spinal cord injury, new research suggests.

16 Nov 2010